Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMCR Stock Forecast 2025-2026
$27.69
Current Price
$1.39B
Market Cap
Buy 12
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to IMCR Price Targets
+261.1%
To High Target of $100.00
+129.3%
To Median Target of $63.50
-10.8%
To Low Target of $24.71
IMCR Price Momentum
-2.5%
1 Week Change
-0.6%
1 Month Change
-49.0%
1 Year Change
-6.1%
Year-to-Date Change
-52.6%
From 52W High of $58.36
+19.6%
From 52W Low of $23.15
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Immunocore (IMCR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IMCR and similar high-potential opportunities.
Latest IMCR Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, IMCR has a bullish consensus with a median price target of $63.50 (ranging from $24.71 to $100.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $27.69, the median forecast implies a 129.3% upside. This outlook is supported by 12 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 261.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMCR Analyst Ratings
12
Buy
3
Hold
1
Sell
IMCR Price Target Range
Low
$24.71
Average
$63.50
High
$100.00
Current: $27.69
Latest IMCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $86.00 |
| Apr 14, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $50.00 |
| Apr 10, 2025 | Needham | Gil Blum | Buy | Reiterates | $71.00 |
| Apr 7, 2025 | Mizuho | Graig Suvannavejh | Neutral | Maintains | $33.00 |
| Mar 12, 2025 | Needham | Gil Blum | Buy | Reiterates | $71.00 |
| Mar 12, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
| Mar 7, 2025 | Morgan Stanley | Andrew Galler | Equal-Weight | Assumes | $35.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
| Feb 27, 2025 | Needham | Gil Blum | Buy | Reiterates | $71.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
| Jan 10, 2025 | Needham | Buy | Reiterates | $0.00 | |
| Dec 13, 2024 | Morgan Stanley | Andrew Galler | Equal-Weight | Downgrade | $35.00 |
| Nov 11, 2024 | Mizuho | Graig Suvannavejh | Neutral | Downgrade | $38.00 |
| Nov 7, 2024 | Needham | Gil Blum | Buy | Maintains | $71.00 |
| Oct 24, 2024 | UBS | David Dai | Sell | Initiates | $24.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
| Oct 11, 2024 | Morgan Stanley | Andrew Galler | Overweight | Maintains | $74.00 |
| Oct 7, 2024 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $0.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Immunocore Holdings plc – ADR (IMCR) Competitors
The following stocks are similar to Immunocore based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immunocore Holdings plc – ADR (IMCR) Financial Data
Immunocore Holdings plc – ADR has a market capitalization of $1.39B with a P/E ratio of -28.5x. The company generates $333.58M in trailing twelve-month revenue with a -6.5% profit margin.
Revenue growth is +33.2% quarter-over-quarter, while maintaining an operating margin of -3.9% and return on equity of -5.9%.
Valuation Metrics
Market Cap
$1.39B
Enterprise Value
$1.03B
P/E Ratio
-28.5x
PEG Ratio
-16.2x
Price/Sales
4.2x
Growth & Margins
Revenue Growth (YoY)
+33.2%
Gross Margin
+99.1%
Operating Margin
-3.9%
Net Margin
-6.5%
EPS Growth
+0.1%
Financial Health
Cash/Price Ratio
+60.2%
Current Ratio
6.4x
Debt/Equity
114.7x
ROE
-5.9%
ROA
-1.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Immunocore Holdings plc – ADR (IMCR) Business Model
About Immunocore Holdings plc – ADR
What They Do
Develops innovative T cell receptor therapies.
Business Model
Immunocore Holdings plc generates revenue through the development and commercialization of T cell receptor (TCR) therapies aimed at treating cancer, autoimmune disorders, and infectious diseases. By leveraging its proprietary ImmTAC technology, the company provides unique therapeutic solutions that meet significant medical needs, positioning itself as a leader in the rapidly growing immunotherapy market.
Additional Information
As an American Depository Receipt (ADR), Immunocore offers US investors a simplified way to invest in its UK-based operations, facilitating access to high-growth opportunities within the biotechnology sector. The company's pioneering research and commitment to advancing immunotherapy could potentially transform treatment methodologies for critical health challenges globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
497
CEO
Dr. Bahija Jallal Ph.D.
Country
United Kingdom
IPO Year
2021
Website
www.immunocore.comImmunocore Holdings plc – ADR (IMCR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
May 09, 2025
By Zacks Equity Research
Analyst Blog
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
May 06, 2025
By Zacks Equity Research
Analyst Blog
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
May 06, 2025
By Zacks Equity Research
Analyst Blog
Latest News
New Strong Buy Stocks for May 8th
7 days ago
Quick Summary
BTSG, NWFL, MNRO, UBSI, and IMCR were added to the Zacks Rank #1 (Strong Buy) List on May 8, 2025.
Why It Matters
BTSG, NWFL, MNRO, UBSI, and IMCR receiving a Zacks Rank #1 indicates strong performance expectations, signaling potential investment opportunities for high returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immunocore reported Q1 2025 net revenues of $93.9M for KIMMTRAK®, a 33% year-over-year increase. They expect to complete enrollment for the Phase 3 TEBE-AM trial in 1H 2026 and have $837M in cash.
Why It Matters
Immunocore's strong revenue growth and robust pipeline progress signal financial health and potential for future value, enhancing investor confidence and interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immunocore (IMCR) reported its quarterly performance for March 2025, suggesting a comparison of key metrics against Wall Street estimates and the previous year’s results is advisable.
Why It Matters
Immunocore's quarterly performance relative to Wall Street estimates and prior year metrics indicates its growth trajectory and market competitiveness, impacting stock valuation and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet
15 days ago
Quick Summary
Wall Street analysts project a 107.5% upside for Immunocore (IMCR), supported by a positive trend in earnings estimate revisions.
Why It Matters
The 107.5% potential upside in price targets for Immunocore signals strong growth expectations, while positive earnings revisions may further boost the stock's appeal.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immunocore will present at upcoming investor conferences, indicating potential engagement with investors and updates on company developments.
Why It Matters
Immunocore's conference presentations may signal upcoming developments or data releases, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The biotech industry is rebounding, with several firms going public this year, particularly those developing obesity treatments and gene therapies, indicating strong future potential.
Why It Matters
A biotech rebound signals potential growth and investment opportunities, especially in lucrative areas like obesity treatments and gene therapies, which may drive stock valuations higher.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Frequently Asked Questions About IMCR Stock
What is Immunocore Holdings plc – ADR's (IMCR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Immunocore Holdings plc – ADR (IMCR) has a median price target of $63.50. The highest price target is $100.00 and the lowest is $24.71.
Is IMCR stock a good investment in 2025?
According to current analyst ratings, IMCR has 12 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $27.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMCR stock?
Wall Street analysts predict IMCR stock could reach $63.50 in the next 12 months. This represents a 129.3% increase from the current price of $27.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immunocore Holdings plc – ADR's business model?
Immunocore Holdings plc generates revenue through the development and commercialization of T cell receptor (TCR) therapies aimed at treating cancer, autoimmune disorders, and infectious diseases. By leveraging its proprietary ImmTAC technology, the company provides unique therapeutic solutions that meet significant medical needs, positioning itself as a leader in the rapidly growing immunotherapy market.
What is the highest forecasted price for IMCR Immunocore Holdings plc – ADR?
The highest price target for IMCR is $100.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 261.1% increase from the current price of $27.69.
What is the lowest forecasted price for IMCR Immunocore Holdings plc – ADR?
The lowest price target for IMCR is $24.71 from at , which represents a -10.8% decrease from the current price of $27.69.
What is the overall IMCR consensus from analysts for Immunocore Holdings plc – ADR?
The overall analyst consensus for IMCR is bullish. Out of 19 Wall Street analysts, 12 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $63.50.
How accurate are IMCR stock price projections?
Stock price projections, including those for Immunocore Holdings plc – ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 1:20 AM UTC